Before beginning any discussion of advanced prostate cancer, it is importantto point out that early detection of the disease has dramatically reducedthe cohort of men who present with locally advanced or metastatic disease.A review of the Eastern Virginia Medical School database indicates that,of the 320 new diagnoses of prostate cancer in 2003, only 5% presented withstage T3 disease, and 7% presented with stage M+ disease.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.